A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS 45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Garcia-Manero, G., Luger, S., Venugopal, P., Maness, L., Wetzler, M., Coutre, S., Stock, W., Borthakur, G., Chiao, J., Kantarjian, H. AMER SOC CLINICAL ONCOLOGY. 2009

View details for Web of Science ID 000276606605012